Market revenue in 2023 | USD 1,078.3 million |
Market revenue in 2030 | USD 2,006.3 million |
Growth rate | 9.3% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.7% in 2023. Horizon Databook has segmented the China rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The China rheumatoid arthritis therapeutics market is witnessing significant advancements with the introduction of innovative treatments and the progression of clinical trials. Key developments have emerged recently, showcasing the evolving landscape of RA treatment in the country.
In March 2022, Shanghai Henlius Biotech, Inc. received approval from the National Medical Products Administration (NMPA) for its rituximab injection in combination with methotrexate for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have inadequate responses to TNF-alpha antagonist therapies.
This approval provides an alternative treatment option for patients with autoimmune diseases and contributes to the diversification of RA therapies available in China. These developments reflect the growing investment in research and development within the RA therapeutics market in China.
Horizon Databook provides a detailed overview of country-level data and insights on the China rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into China rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account